Medical technology startup Evident Vascular has launched with $35m in Series A financing from Vensana Capital for the development of an intravascular ultrasound (IVUS) platform.

Leveraging artificial intelligence, Evident Vascular is developing the next-generation platform to facilitate better imaging and streamlined workflows.

Vensana Capital managing partner Justin Klein said: “The impetus to launch Evident Vascular was born out of the Vensana team’s extensive experience in the vascular space.

“Our team has partnered with entrepreneurs across multiple emerging therapeutic categories in vascular disease over the last two decades, including endovascular aortic aneurysm grafts, drug-coated balloons, venous stents, arterial tacks and thrombectomy devices.”

The IVUS transcatheter intravascular imaging technique is designed to capture images from inside blood vessels to assess vascular disease and guide interventional treatment.

This technique has established a consistent presence in coronary procedures and its potential in both coronary and peripheral interventions is being fuelled by substantial clinical trial data, contributing to future market expansion.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Evident Vascular CEO and co-founder Howard Rosen said: “Legacy IVUS platforms were originally designed primarily for coronary procedures and secondarily for peripheral vascular applications.

“Shortcomings in image quality, interpretation and workflow have limited the widespread adoption of IVUS despite its clinical benefit and there has been minimal innovation to address these limitations.”